The $10B TAVR Market Grew. Why Are Most Patients Still Untreated?
After decades of device-delivery progress, the next era of TAVR must be judged by valve design, physiologic blood flow, and clinical outcomes. With DurAVR® THV, Anteris is bringing a pharma-style disease-management mindset to a category long defined by engineering. MINNEAPOLIS, July 13,...
After decades of device-delivery progress, the next era of TAVR must be judged by valve design, physiologic blood flow, and clinical outcomes. With DurAVR® THV, Anteris is bringing a pharma-style disease-management mindset to a category long defined by engineering. MINNEAPOLIS, July 13,...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.